Cervical cancer is a common malignant tumor in the female reproductive tract system, ranking second in female malignant tumors, and has been characterized by high incidence and low age in recent years, which has seriously endangered women’s health and lives. Statistics from the World Health Organization show that there are about 500,000 new cases of cervical cancer and more than 200,000 deaths from cervical cancer worldwide each year, of which, 80% of deaths occur in developing countries. High-risk HpV infection is the main factor in the occurrence of cervical cancer, and more than 90% of cervical cancer is caused by HpV infection. The International Agency for Research on Cancer clearly suggests that high-risk HPV infection is necessary for the pathogenesis of cervical cancer. Therefore, screening for high-risk HPV is of great importance for the prevention and treatment of cervical cancer. In developed countries, this test has been included as a routine screening program, and it is recommended that all women who have been sexually active for more than three years should undergo this test. Although gynecologists are now aware of the significance of HPV typing for the diagnosis and prevention of cervical cancer, and developed countries have established a comprehensive cervical cancer screening system, there is a lack of effective preventive and therapeutic drugs in clinical practice. There are currently no ideal drugs on the market in China that directly remove and kill the HpV virus.